Literature DB >> 19727301

Seasonality and the changing adult/child prescription ratios in ADHD therapy.

Elisa Cascade1, Amir H Kalali, Richard H Weisler, Susan Lenderts.   

Abstract

Approximately seven million people were prescribed a treatment for attention deficit hyperactivity disorder (ADHD) between November, 2006, and October, 2007: 3.8 million ages 0 to 17 years and 3.2 million age 18 years and older. To investigate prescribing trends, we obtained monthly total prescriptions from January, 2003, through October, 2007, for two age groups: patients under 18 years and patients age 18 years and older. The 0 to 17 years age group has demonstrated significant seasonality with total monthly prescription volume dropping between 22 and 29 percent between May and July, depending on the year. In contrast, prescribing trends for adults age 18 years and older have been steadily growing over the time period and do not exhibit any seasonal variation. Interestingly, in July, 2007, for the first time, ADHD total prescriptions for adults were larger than total prescriptions for children.

Entities:  

Keywords:  ADHD; adolescents; adults; children; prescription; seasonailty

Year:  2008        PMID: 19727301      PMCID: PMC2719546     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  6 in total

1.  Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina.

Authors:  Andrew S Rowland; David M Umbach; Lil Stallone; A Jack Naftel; E Michael Bohlig; Dale P Sandler
Journal:  Am J Public Health       Date:  2002-02       Impact factor: 9.308

2.  Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community.

Authors:  Joseph Biederman; Stephen V Faraone; Thomas J Spencer; Eric Mick; Michael C Monuteaux; Megan Aleardi
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

3.  The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Lenard Adler; Russell Barkley; Joseph Biederman; C Keith Conners; Olga Demler; Stephen V Faraone; Laurence L Greenhill; Mary J Howes; Kristina Secnik; Thomas Spencer; T Bedirhan Ustun; Ellen E Walters; Alan M Zaslavsky
Journal:  Am J Psychiatry       Date:  2006-04       Impact factor: 18.112

4.  Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning.

Authors:  Russell A Barkley; Kevin R Murphy; George I Dupaul; Tracie Bush
Journal:  J Int Neuropsychol Soc       Date:  2002-07       Impact factor: 2.892

Review 5.  Impact of substance use disorder on ADHD and its treatment.

Authors:  Timothy E Wilens; Himanshu P Upadhyaya
Journal:  J Clin Psychiatry       Date:  2007-08       Impact factor: 4.384

6.  Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature.

Authors:  Timothy E Wilens; Stephen V Faraone; Joseph Biederman; Samantha Gunawardene
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

  6 in total
  5 in total

1.  Brief and extended abstinence from chronic oral methylphenidate treatment produces reversible behavioral and physiological effects.

Authors:  Leanna Kalinowski; Carly Connor; Rathini Somanesan; Emily Carias; Kaleigh Richer; Lauren Smith; Connor Martin; Macauley Mackintosh; Daniel Popoola; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos
Journal:  Dev Psychobiol       Date:  2019-08-27       Impact factor: 3.038

2.  ADHD medication use following FDA risk warnings.

Authors:  Colleen L Barry; Andres Martin; Susan H Busch
Journal:  J Ment Health Policy Econ       Date:  2012-09

3.  Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty - United States, 2014-2019.

Authors:  Amy R Board; Gery Guy; Christopher M Jones; Brooke Hoots
Journal:  Drug Alcohol Depend       Date:  2020-09-15       Impact factor: 4.492

4.  Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.

Authors:  David B Clemow; Allen W Nyhuis; Rebecca L Robinson
Journal:  CNS Neurosci Ther       Date:  2016-07-31       Impact factor: 5.243

5.  What stops practitioners discussing medication breaks in children and adolescents with ADHD? Identifying barriers through theory-driven qualitative research.

Authors:  Kinda Ibrahim; Parastou Donyai
Journal:  Atten Defic Hyperact Disord       Date:  2018-07-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.